Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Qiu C, De Ronchi D, Fratiglioni L: The epidemiology of the dementias: an update. Curr. Opin. Psychiatry20,380–385 (2007).
  MedlineGoogle Scholar
• 2  Alzheimer ’s Association: Alzheimer’s disease facts and figures. Alzheimers Dement.6(2),158–194 (2010).
  MedlineGoogle Scholar
• 3  Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM: Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement.3(3),186–191 (2007).
  MedlineGoogle Scholar
• 4  Panza F, Solfrizzi V, Frisardi V et al.: Disease-modifying approach to the treatment of Alzheimer’s disease: from α-secretase activators to γ-secretase inhibitors and modulators. Drugs Aging26(7),537–555 (2009).
  Medline CASGoogle Scholar
• 5  Panza F, Solfrizzi V, Frisardi V et al.: Beyond the neurotransmitter-focused approach in treating Alzheimer’s disease: drugs targeting β-amyloid and tau protein. Aging Clin. Exp. Res.21(6),386–406 (2009).
  Medline CASGoogle Scholar
• 6  Frisardi V, Solfrizzi V, Imbimbo PB et al.: Towards disease-modifying treatment of Alzheimer’s disease: drugs targeting β-amyloid. Curr. Alzheimer Res.7(1),40–55 (2010).
  Medline CASGoogle Scholar
• 7  Sabbagh MN: Drug development for Alzheimer’s disease: where are we now and where we are headed? Am. J. Geriatr. Pharmacother.7(3),167–185 (2010).
  Google Scholar
• 8  Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M: Alzheimer’s disease: clinical trials and drug development. Lancet Neurol.9(7),702–716 (2010).
  Medline CASGoogle Scholar
• 9  Citron M: Alzheimer’s disease: strategies for disease modification. Nat. Rev. Drug Discov.9(5),387–398 (2010).
  Medline CASGoogle Scholar
• 10  Walter J, Kaether C, Steiner H, Haass C: The cell biology of Alzheimer’s disease: uncovering the secrets of secretases. Curr. Opin. Neurobiol.11(5),585–590 (2001).
  Medline CASGoogle Scholar
• 11  Hardy J, Allsop D: Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol. Sci.12(5),383–388 (1991).
  Medline CASGoogle Scholar
• 12  Wisniewski KE, Wisniewski HM, Wen GY: Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome. Ann. Neurol.17(3),278–282 (1985).
  Medline CASGoogle Scholar
• 13  Kawahara M: Neurotoxicity of β-amyloid protein: oligomerization, channel formation, and calcium dyshomeostasis. Curr. Pharm. Des.16(25),2779–2789 (2010).
  Medline CASGoogle Scholar
• 14  Brion JP, Ando K, Heraud C, Leroy K: Modulation of tau pathology in tau transgenic models. Biochem. Soc. Trans.38(4),996–1000 (2010).
  Medline CASGoogle Scholar
• 15  McDonald JM, Savva GM, Brayne C et al.: Medical research council cognitive function and ageing study; the presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia. Brain133(Pt 5),1328–1341 (2010).
  MedlineGoogle Scholar
• 16  Krafft GA, Klein WL: ADDLs and the signaling web that leads to Alzheimer’s disease. Neuropharmacology59(4–5),230–242 (2010).
  Medline CASGoogle Scholar
• 17  Castellani RJ, Lee HG, Zhu X, Perry G, Smith MA: Alzheimer disease pathology as a host response. J. Neuropathol. Exp. Neurol.67(6),523–531 (2008).
  Medline CASGoogle Scholar
• 18  Scheinin NM, Aalto S, Koikkalainen J et al.: Follow-up of [¹¹C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology73(15),1186–1192 (2009).
  Medline CASGoogle Scholar
• 19  Knopman DS, Parisi JE, Salviati A et al.: Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol.62(11),1087–1095 (2003).
  Medline CASGoogle Scholar
• 20  Morris JC, Roe CM, Grant EA et al.: Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol.66(12),1469–1475 (2009).
  MedlineGoogle Scholar
• 21  Vickers JC, Chin D, Edwards AM, Sampson V, Harper C, Morrison J: Dystrophic neurite formation associated with age-related β-amyloid deposition in the neocortex: clues to the genesis of neurofibrillary pathology. Exp. Neurol.141(1),1–11 (1996).
  Medline CASGoogle Scholar
• 22  Imbimbo BP, Solfrizzi V, Panza F: Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment? Front. Aging Neurosci.2,19 (2010).
  Medline CASGoogle Scholar
• 23  Hüll M, Berger M, Heneka M: Disease-modifying therapies in Alzheimer’s disease: how far have we come? Drugs66(16),2075–2093 (2006).
  Medline CASGoogle Scholar
• 24  Panza F, D’Introno A, Colacicco AM et al.: Lipid metabolism in cognitive decline and dementia. Brain Res. Rev.51(2),275–292 (2006).
  Medline CASGoogle Scholar
• 25  Martenyi F, Lowe S, Dean RA et al.: Central and peripheral pharmacokinetics and pharmacodynamic effects of the β-site APP cleavage enzyme (BACE1) inhibitor LY2811376 in humans. Presented at: ICAD 2010. Honolulu, HI, USA, 10–15 July 2010.
  Google Scholar
• 26  Panza F, Frisardi V, Imbimbo BP, Capurso C et al.: γ-secretase inhibitors for the treatment of Alzheimer’s disease: the current state. CNS Neurosci. Ther. DOI: 10.1111/j.1755–5949.2010.00164.x (2010) (Epub ahead of print).
  MedlineGoogle Scholar
• 27  Faux NG, Ritchie CW, Gunn A et al.: PBT2 rapidly improves cognition in Alzheimer’s disease: additional Phase II analyses. J. Alzheimers Dis.20(2),509–516 (2010).▪ Post-hoc analysis of the Phase II trial examining PBT2, confirming the positive cognitive effects of this zinc/copper ionophore in Alzheimer’s disease (AD) patients.
  Medline CASGoogle Scholar
• 28  Wisniewski T, Konietzko U: amyloid-β immunisation for Alzheimer’s disease. Lancet Neurol.7(9),805–811 (2008).▪ Comprehensive review discussing β-amyloid (Aβ) immunization in AD, with a special focus on possible mechanisms of Aβ-directed immunomodulation.
  Medline CASGoogle Scholar
• 29  Cribbs DH: Aβ DNA vaccination for Alzheimer’s disease: focus on disease prevention. CNS Neurol. Disord. Drug Targets9(2),207–216 (2010).
  Medline CASGoogle Scholar
• 30  Solomon B, Koppel R, Hanan E, Katzav T: Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc. Natl Acad. Sci. USA93(1),452–455 (1996).▪ To the best of our knowledge, this was the first report in which it was found that monoclonal antibodies raised against Aβ peptide inhibited its aggregation.
  Medline CASGoogle Scholar
• 31  Schenk D, Barbour R, Dunn W et al.: Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature400(6740),173–177 (1999).▪ First description of Aβ vaccination and plaque removal in amyloid precursor protein transgenic mice, an animal model of AD.
  Medline CASGoogle Scholar
• 32  Kennedy GJ, Golde TE, Tariot PN, Cummings JL: amyloid-based interventions in Alzheimer’s disease. CNS Spectr.12(12 Suppl. 1),1–14 (2007).
  Google Scholar
• 33  Bacskai BJ, Kajdasz ST, Christie RH et al.: Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med.7(3),369–372 (2001).
  Medline CASGoogle Scholar
• 34  Solomon B, Koppel R, Hanan E, Katzav T: Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc. Natl Acad. Sci. USA93(1),452–455 (1996).
  Medline CASGoogle Scholar
• 35  Bard F, Cannon C, Barbour R et al.: Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med.6(8),916–919 (2000).
  Medline CASGoogle Scholar
• 36  Bacskai BJ, Kajdasz ST, McLellan ME et al.: Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J. Neurosci.22(18),7873–7878 (2002).
  Medline CASGoogle Scholar
• 37  Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE: amyloid-β immunization effectively reduces amyloid deposition in FcRg^-/- knock-out mice. J. Neurosci.23(24),8532–8538 (2003).
  Medline CASGoogle Scholar
• 38  DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM: Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA98,8850–8855 (2001).▪ To the best of our knowledge, this was the first study showing that antibodies could prevent Aβ deposition with the creation of a peripheral sink effect, in which the removal of excess circulatory soluble Aβ draws soluble Aβ from the brain.
  Medline CASGoogle Scholar
• 39  Sigurdsson EM, Scholtzova H, Mehta P, Frangione B, Wisniewski T: Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer’s disease associated pathology in transgenic mice. Am. J. Pathol.159(2),439–447 (2001).
  Medline CASGoogle Scholar
• 40  Sigurdsson EM, Knudsen E, Asuni A et al.: An attenuated immune response is sufficient to enhance cognition in an Alzheimer’s disease mouse model immunized with amyloid-β derivatives. J. Neurosci.24(28),6277–6282 (2004).
  Medline CASGoogle Scholar
• 41  Brody DL, Holtzman DM: Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci.31,175–193 (2008).
  Medline CASGoogle Scholar
• 42  Bayer AJ, Bullock R, Jones RW et al.: Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology64(1),94–101 (2005).▪▪ Phase I trial of AN1792 on 80 mild-to-moderate AD patients, and the first published account of Aβ immunization in humans.
  Medline CASGoogle Scholar
• 43  Gilman S, Koller M, Black RS et al.: Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology64(9),1553–1562 (2005).▪▪ Phase II trial of AN1792, interrupted for the development of meningoencephalitis in 6% of AD patients.
  Medline CASGoogle Scholar
• 44  Robinson SR, Bishop GM, Lee HG, Munch G: Lessons from the AN1792 Alzheimer vaccine: lest we forget. Neurobiol. Aging25(5),609–615 (2004).
  Medline CASGoogle Scholar
• 45  Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS: Progress in the active immunotherapeutic approach to Alzheimer’s disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener. Dis.5(3–4),194–196 (2008).
  Medline CASGoogle Scholar
• 46  Bombois S, Maurage CA, Gompel M et al.: Absence of β-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch. Neurol.64(4),583–587 (2007).
  MedlineGoogle Scholar
• 47  Ferrer I, Boada Rovira M, Sánchez Guerra ML, Rey MJ, Costa-Jussá F: Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer’s disease. Brain Pathol.14(1),11–20 (2004).▪ Helped to define the pathology of meningoencephalitis in AN1792-treated patients.
  Medline CASGoogle Scholar
• 48  Masliah E, Hansen L, Adame A et al.: Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology64(1),129–131 (2005).▪▪ To the best of our knowledge, this was the first report of brain pathology in an AN1792-treated patient who did not develop meningoencephalitis, suggesting that Aβ clearance could occur in the absence of a symptomatic neuroinflammatory reaction.
  Medline CASGoogle Scholar
• 49  Hock C, Konietzko U, Streffer JR et al.: Antibodies against β-amyloid slow cognitive decline in Alzheimer’s disease. Neuron38(4),547–554 (2003).
  Medline CASGoogle Scholar
• 50  Holmes C, Boche D, Wilkinson D et al.: Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled Phase I trial. Lancet372(9634),216–223 (2008).▪▪ This case series demonstrated that the burden of Aβ correlated inversely with antibody titer. Although this was not the first postmortem study of an AN1792-treated patient, it strongly suggested that Aβ immunization facilitated plaque clearance in humans; however, doing so had no effect on survival or progression of dementia.
  Medline CASGoogle Scholar
• 51  Frautschy SA, Baird A, Cole GM: Effects of injected Alzheimer β-amyloid cores in rat brain. Proc. Natl Acad. Sci. USA88(19),8362–8366 (1991).
  Medline CASGoogle Scholar
• 52  Sigurdsson EM, Lee JM, Dong XW, Hejna MJ, Lorens SA: Bilateral injections of amyloid-β 25–35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects. Neurobiol. Aging18(6),591–608 (1997).
  Medline CASGoogle Scholar
• 53  Götz J, Chen F, van Dorpe J, Nitsch RM: Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Aβ42 fibrils. Science293(5534),1491–1495 (2001).
  Medline CASGoogle Scholar
• 54  Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM: Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron43(3),321–332 (2004).
  Medline CASGoogle Scholar
• 55  Boche D, Donald J, Love S, Neal JW, Holmes C, Nicoll J: Aβ42 immunisation reduces both tau and Aβ deposits in Alzheimer’s disease. Presented at: ICAD 2010. Honolulu, HI, USA, 10–15 July 2010.
  Google Scholar
• 56  Lemere CA, Masliah E: Can Alzheimer disease be prevented by amyloid-β immunotherapy? Nat. Rev. Neurol.6(2),108–119 (2010).▪ Influential review article that provided an update on the active and passive Aβ immunotherapies currently in clinical trials.
  Medline CASGoogle Scholar
• 57  Tabira T: Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J. Exp. Med.220(2),95–106 (2010).
  Medline CASGoogle Scholar
• 58  Muhs A, Hickman DT, Pihlgren M et al.: Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc. Natl Acad. Sci. USA104(23),9810–9815 (2007).
  Medline CASGoogle Scholar
• 59  Frenkel D, Dewachter I, Van Leuven F, Solomon B: Reduction of β-amyloid plaques in brain of transgenic mouse model of Alzheimer’s disease by EFRH-phage immunization. Vaccine21(11–12),1060–1065 (2003).
  Medline CASGoogle Scholar
• 60  Agadjanyan MG, Ghochikyan A, Petrushina I et al.: Prototype Alzheimer’s disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol.174(3),1580–1586 (2005).
  Medline CASGoogle Scholar
• 61  Petrushina I, Ghochikyan A, Mktrichyan M et al.: Alzheimer’s disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Aβ species in amyloid precursor protein transgenic mice. J. Neurosci.27(46),12721–12731 (2007).
  Medline CASGoogle Scholar
• 62  Nikolic WV, Bai Y, Obregon D et al.: Transcutaneous β-amyloid immunization reduces cerebral β-amyloid deposits without T cell infiltration and microhemorrhage. Proc. Natl Acad. Sci. USA104(7),2507–2512 (2007).
  Medline CASGoogle Scholar
• 63  Bowers WJ, Mastrangelo MA, Stanley HA, Casey AE, Milo LJ Jr, Federoff HJ: HSV amplicon-mediated Aβ vaccination in Tg2576 mice: differential antigenspecific immune responses. Neurobiol. Aging26(4),393–407 (2005).
  Medline CASGoogle Scholar
• 64  Youm JW, Kim H, Han JH et al.: Transgenic potato expressing Aβ reduce Aβ burden in Alzheimer’s disease mouse model. FEBS Lett.579(30),6737–6744 (2005).
  Medline CASGoogle Scholar
• 65  Youm JW, Jeon JH, Kim H et al.: Transgenic tomatoes expressing human β-amyloid for use as a vaccine against Alzheimer’s disease. Biotechnol. Lett.30(10),1839–1645 (2008).
  Medline CASGoogle Scholar
• 66  Okura Y, Miyakoshi A, Kohyama K, Park IK, Staufenbiel M, Matsumoto Y: Nonviral Aβ DNA vaccine therapy against Alzheimer’s disease: long-term effects and safety. Proc. Natl Acad. Sci. USA103(25),9619–9624 (2006).
  Medline CASGoogle Scholar
• 67  Movsesyan N, Ghochikyan A, Mkrtichyan M et al.: Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine – a novel immunotherapeutic strategy. PLoS One3,E2124 (2008).
  MedlineGoogle Scholar
• 68  Bach P, Tschäpe JA, Kopietz F et al.: Vaccination with Aβ-displaying virus-like particles reduces soluble and insoluble cerebral Aβ and lowers plaque burden in APP transgenic mice. J. Immunol.182(12),7613–7624 (2008).
  Google Scholar
• 69  Lemere CA, Maron R, Selkoe DJ, Weiner HL: Nasal vaccination with β-amyloid peptide for the treatment of Alzheimer’s disease. DNA Cell. Biol.20(11),705–711 (2001).
  Medline CASGoogle Scholar
• 70  Zhang J, Wu X, Qin C et al.: A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and β-amyloid plaques in a mouse model of Alzheimer’s disease. Neurobiol. Dis.14(3),365–379 (2003).
  Medline CASGoogle Scholar
• 71  Weiner HL, Lemere CA, Maron R et al.: Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer’s disease. Ann. Neurol.48(4),567–579 (2000).
  Medline CASGoogle Scholar
• 72  Jicha GA: Is passive immunization for Alzheimer’s disease ‘alive and well’ or ‘dead and buried’? Expert Opin. Biol. Ther.9(4),481–491 (2009).
  Medline CASGoogle Scholar
• 73  Morgan D: Mechanisms of Aβ-plaque clearance following passive Aβ-immunization. Neurodegener. Dis.2(5),261–266 (2005).
  Medline CASGoogle Scholar
• 74  Lichtlen P, Mohajeri MH: Antibody-based approaches in Alzheimer’s research: safety, pharmacokinetics, metabolism, and analytical tools. J. Neurochem.104(4),859–874 (2008).
  Medline CASGoogle Scholar
• 75  Walsh DM, Selkoe DJ: Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett.11(3),213–228 (2004).
  Medline CASGoogle Scholar
• 76  Kerchner GA, Boxer AL: Bapineuzumab. Expert Opin. Biol. Ther.10(7),1121–1130 (2010).
  Medline CASGoogle Scholar
• 77  Seubert P, Vigo-Pelfrey C, Esch F et al.: Isolation and quantification of soluble Alzheimer’s β-peptide from biological fluids. Nature359(6393),325–327 (1992).
  Medline CASGoogle Scholar
• 78  Siemers ER, Friedrich S, Dean RA et al.: Safety and changes in plasma and cerebrospinal fluid amyloid-β after a single administration of an amyloid-β monoclonal antibody in subjects with Alzheimer disease. Clin. Neuropharmacol.33(2),67–73 (2010).
  Medline CASGoogle Scholar
• 79  DeMattos RB, Racke MM, Gelfanova V et al.: Identification, characterization, and comparison of amino-terminally truncated Aβ42 peptides in Alzheimer’s disease brain tissue and in plasma from Alzheimer’s patients receiving solanezumab immunotherapy treatment. Alzheimers Dement.5,P156–P157 (2009).
  Google Scholar
• 80  Seubert P, Barbour R, Khan K et al.: Antibody capture of soluble Aβ does not reduce cortical Aβ amyloidosis in the PDAPP mouse. Neurodegener Dis.5(2),65–71 (2008).
  Medline CASGoogle Scholar
• 81  Yamada K, Yabuki C, Seubert P et al.: Aβ immunotherapy: intracerebral sequestration of Aβ by an anti-Aβ monoclonal antibody 266 with high affinity to soluble Aβ. J. Neurosci.29(36),11393–11398 (2009).▪ Questioned the peripheral sink hypothesis, suggesting that solanezumab may be effective by stabilizing Aβ monomers and preventing formation of Aβ oligomers.
  Medline CASGoogle Scholar
• 82  Siemers ER, Friedrich S, Dean RA et al.: P4–346: safety, tolerability and biomarker effects of an Aβ monoclonal antibody administered to patients with Alzheimer’s disease. Alzheimers Dement.4,T774 (2008).
  Google Scholar
• 83  Racke MM, Boone LI, Hepburn DL et al.: Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid b. J. Neurosci.25(3),629–636 (2005).
  Medline CASGoogle Scholar
• 84  Nicholas T, Knebel W, Gastonguay MR et al.: Preliminary population pharmacokinetic modeling of PF-04360365, a humanized anti-amyloid monoclonal antibody, in patients with mild-to-moderate Alzheimer’s disease. Alzheimers Dement.5,P253 (2009).
  Google Scholar
• 85  Watts RJ, Chen M, Atwal J et al.: Selection of an anti-Aβ antibody that binds various forms of Aβ and blocks toxicity both in vitro and in vivo. Alzheimers Dement.5,P426 (2009).
  Google Scholar
• 86  Relkin NR: Natural human antibodies targeting amyloid aggregates in intravenous immunoglobulin. Alzheimers Dement.4,T101 (2008).
  Google Scholar
• 87  Du Y, Wei X, Dodel R et al.: Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity. Brain126(Pt 9),1935–1939 (2003).
  MedlineGoogle Scholar
• 88  Ma QL, Lim GP, Harris-White ME et al.: Antibodies against β-amyloid reduce Aβ oligomers, glycogen synthase kinase-3b activation and tau phosphorylation in vivo and in vitro. J. Neurosci. Res.83(3),374–384 (2006).
  Medline CASGoogle Scholar
• 89  Istrin G, Bosis E, Solomon B: Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-β peptide. J. Neurosci. Res.84(2),434–443 (2006).
  Medline CASGoogle Scholar
• 90  Dodel RC, Du Y, Depboylu C et al.: Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry75(10),1472–1474 (2004).
  Medline CASGoogle Scholar
• 91  Relkin NR, Szabo P, Adamiak B et al.: 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging30(11),1728–1736 (2009).▪ After the trial of Dodel and colleagues [90], this was the second small trial of intravenous immunoglobulin infusions for treatment of AD. In particular, this first American trial was longer, slightly larger and showed a possible benefit on the Mini Mental Scale Examination, forming the basis of Phase II and III trials by the same group in collaboration with Baxter and the NIH-sponsored Alzheimer’s Disease Cooperative Study.
  Medline CASGoogle Scholar
• 92  Johnson-Wood K, Lee M, Motter R et al.: Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA94(4),1550–1555 (1997).
  Medline CASGoogle Scholar
• 93  Black RS, Sperling RA, Safirstein B et al.: A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord.24(2),198–203 (2010).▪ Phase I, third-party unblinded, single ascending dose trial that examined 30 patients with mild-to-moderate AD receiving bapineuzumab infusion of 0.5, 1.5 or 5 mg/kg, or placebo.
  Medline CASGoogle Scholar
• 94  Salloway S, Sperling R, Gilman S et al.: A Phase II multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology73(24),2061–2070 (2009).▪▪ Main Phase II trial of bapineuzumab.
  Medline CASGoogle Scholar
• 95  Rinne JO, Brooks DJ, Rossor MN et al.: ¹¹C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer’s disease treated with bapineuzumab: a Phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol.9(4),363–372 (2010).▪▪ Phase II trial of bapineuzumab in British and Finnish cohorts that demonstrated convincing in vivo evidence that the monoclonal antibody reduced cerebral Aβ levels, using 11C-PiB retention on PET as the primary outcome measure.
  Medline CASGoogle Scholar
• 96  Rabinovici GD, Jagust WJ: Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav. Neurol.21(1),117–128 (2009).
  Medline CASGoogle Scholar
• 97  Blennow K, Zetterberg H, Wei J, Liu E, Black R, Grundman M: Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer’s disease. Alzheimers Dement.6(Suppl.),S134–S135 (2010).
  Google Scholar
• 98  Laskowitz DT, Vitek MP: Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions. Pharmacogenomics8(8),959–969 (2008).
  Google Scholar
• 99  Kim J, Basak JM, Holtzman DM: The role of apolipoprotein E in Alzheimer’s disease. Neuron63(3) 287–303 (2009).
  Medline CASGoogle Scholar
• 100  Schroeter S, Khan K, Barbour R et al.: Immunotherapy reduces vascular amyloid-β in PDAPP mice. J. Neurosci.28(27),6787–6793 (2008).▪ Recent passive immunization study with murine bapineuzumab demonstrated increased incidence of microhemorrhage despite low-vascular amyloid deposition in PDGF promoter expressing amyloid precursor protein mice at 12 months of age, suggesting no direct association between vascular amyloid burden and microhemorrhage.
  Medline CASGoogle Scholar
• 101  Laskowitz DT, Thekdi AD, Thekdi SD et al.: Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp. Neurol.167(1),74–85 (2001).
  Medline CASGoogle Scholar
• 102  Atwood CS, Bishop GM, Perry G, Smith MA: amyloid-β: a vascular sealant that protects against hemorrhage? J. Neurosci. Res.70(3),356 (2002).
  Medline CASGoogle Scholar
• 103  Atwood CS, Bowen RL, Smith MA, Perry G: Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply. Brain Res. Brain Res. Rev.43(1),164–178 (2003).
  Medline CASGoogle Scholar
• 104  Zhang-Nunes SX, Maat-Schieman ML, Van Duinen SG et al.: The cerebral β-amyloid angiopathies: hereditary and sporadic. Brain Pathol.16(1),30–39 (2006).
  Medline CASGoogle Scholar
• 105  Pfeifer M, Boncristiano S, Bondolfi L et al.: Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science298(5597),1379 (2002).
  Medline CASGoogle Scholar
• 106  Racke MM, Boone LI, Hepburn DL et al.: Exacerbation of cerebral amyloid angiopathy-associated microhemorrhages in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyoid β. J. Neurosci.25(3),629–636 (2005).
  Medline CASGoogle Scholar
• 107  Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN: amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience144(3),950–960 (2007).
  Medline CASGoogle Scholar
• 108  Patton RL, Kalback WM, Esh CL et al.: amyloid-β peptide remnants in AN1792-immunized Alzheimer’s disease patients: a biochemical analysis. Am. J. Pathol.169(3),1048–1063 (2006).
  Medline CASGoogle Scholar
• 109  Vellas B, Black R, Thal LJ et al.; AN1792 (QS-21)-251 Study Team: Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res.6(2),144–151 (2009).
  Medline CASGoogle Scholar
• 110  Castellani RJ, Lee HG, Zhu X, Nunomura A, Perry G, Smith MA: Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol.111(6),503–509 (2006).
  MedlineGoogle Scholar
• 111  Lee HG, Zhu X, Nunomura A, Perry G, Smith MA: Amyloid b: the alternate hypothesis. Curr. Alzheimer Res.3(6),75–80 (2006).
  Medline CASGoogle Scholar
• 112  Rottkamp CA, Raina AK, Zhu X et al.: Redox-active iron mediates amyloid-β toxicity. Free Radic. Biol. Med.30(4),447–450 (2001).
  Medline CASGoogle Scholar
• 113  Mura E, Lanni C, Preda S et al.: β-amyloid: a disease target or a synaptic regulator affecting age-related neurotransmitter changes? Curr. Pharm. Des.16(6),672–683 (2010).
  Medline CASGoogle Scholar
• 114  Vossel KA, Zhang K, Brodbeck J et al.: Tau reduction prevents A β-induced defects in axonal transport. Science330(6001),198 (2010).
  Medline CASGoogle Scholar
• 115  Duce JA, Tsatsanis A, Cater MA et al.: Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer’s disease. Cell142(6),857–867 (2010).
  Medline CASGoogle Scholar
• 201  Eli Lilly and Company. Press release: 17 August, 2010. Lilly halts development of semagacestat for Alzheimer’s disease based on preliminary results of Phase III clinical trials http://newsroom.lilly.com/releasedetail.cfm?releaseid=499794
  Google Scholar
• 202  A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease http://clinicaltrials.gov/ct2/show/NCT00818662
  Google Scholar
• 203  Study of Octagam 10% on the Treatment of Mild to Moderate Alzheimer’s Patients http://clinicaltrials.gov/ct2/show/NCT00812565
  Google Scholar
• 204  Bapineuzumab in Patients With Mild to Moderate Alzheimer’s Disease (ApoE4 Carrier) http://clinicaltrials.gov/ct2/show/NCT00575055
  Google Scholar
• 205  Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients http://clinicaltrials.gov/ct2/show/NCT00676143
  Google Scholar
• 206  Bapineuzumab in Patients With Mild to Moderate Alzheimer’s Disease (ApoE4 Non-Carrier) http://clinicaltrials.gov/ct2/show/NCT00574132
  Google Scholar
• 207  Study Evaluating the Efficacy and Safety of Bapineuzumab in Alzheimer Disease Patients http://clinicaltrials.gov/ct2/show/NCT00667810
  Google Scholar
• 208  Elan and Wyeth plan to amend bapineuzumab Phase 3 protocols. Press release http://newsroom.elan.com/phoenix.zhtml?c=88326&p=irol-newsArticle&ID=1272546&highlight=(2009
  Google Scholar
• 209  Study Evaluating the Long-term Safety and Efficacy of Subcutaneous Bapineuzumab http://clinicaltrials.gov/ct2/show/NCT00916617
  Google Scholar
• 210  Study Evaluating Bapineuzumab In Alzheimer Disease Subjects http://clinicaltrials.gov/ct2/show/NCT00663026
  Google Scholar
• 301  Kline EL, McMichael J: Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid protein. WO91/16819 (1991).
  Google Scholar
• 302  Schenk D: Prevention and treatment of amyloidogenic disease. WO99/27944 (1998).
  Google Scholar